#Sweden #Immunovia #Lund #pancreatic cancer #CLARITI study

Immunovia's CLARITI Study Results to Be Presented at the Digestive Disease Week 2025

Introduction
Immunovia AB, a key player in pancreatic cancer diagnostics, has announced that its CLARITI study results will be showcased at the esteemed Digestive Disease Week® (DDW) 2025 conference. This year’s event is set to take place from May 5-6, 2025, and marks the largest international gathering of experts in gastroenterology, hepatology, and related fields.

Prestigious Recognition
During this distinguished conference, the CLARITI study has been selected for a Plenary Oral Presentation, an honor reserved for only a select few studies that demonstrate significant scientific and clinical impact. Specifically, the study was chosen as one of six abstracts that exemplify groundbreaking research, a testament to both the rigor of the methodology and the relevance of the findings in addressing unmet clinical needs in pancreatic cancer detection.

Presentation Details
The findings will be presented by Dr. Aimee Lee Lucas, a highly regarded expert in gastroenterology, who serves as Chief of Gastroenterology and Hepatology at Mount Sinai West and Mount Sinai Morningside Hospitals and as Professor of Medicine at the Icahn School of Medicine. Dr. Lucas has been instrumental in the design and execution of the CLARITI study, significantly contributing to the blood sample collection process.

Her presentation, titled "Clinical validation of a novel blood-based multi-biomarker test for the early detection of pancreatic ductal adenocarcinoma (PDAC) in an independent high-risk population shows similar high performance as observed in its model development study," will provide deep insights into the test's robust performance and its potential implications for early detection of pancreatic cancer.

Expert Commentary
Expressing her enthusiasm for the platform, Dr. Lucas stated, "I am excited to present these data at the world's largest conference for gastroenterologists. Selection of these study results for a distinguished plenary oral presentation underscores the rigor of the CLARITI validation study and the strong performance of the Immunovia test in the study."

Immunovia’s CEO, Jeff Borcherding, echoed this sentiment, expressing pride in the recognition of the CLARITI study as it reinforces the quality of the science behind it. He remarked, "It's a strong statement about the quality of our science and it highlights the importance of the unmet clinical need our new test addresses."

About the CLARITI Study
The CLARITI study was specifically designed to validate a novel blood-based multi-biomarker test aimed at the early detection of pancreatic ductal adenocarcinoma (PDAC) in patients at high risk. Given the increasing incidence of pancreatic cancer and its notoriously poor prognosis, early detection technologies have gained paramount importance.

The study’s outcomes provide considerable evidence supporting the test's applicability in real-world settings, thereby promising to enhance early diagnosis and treatment options for patients.

Digestive Disease Week Overview
Digestive Disease Week (DDW) is an integral event for researchers and physicians in the digestive diseases arena, co-sponsored by esteemed organizations like the American Gastroenterological Association (AGA) and the American Society for Gastrointestinal Endoscopy (ASGE). This year's meeting is anticipated to attract over 13,000 attendees, including global decision-makers, researchers, and clinicians, making it a pivotal venue for exchanging knowledge, ideas, and advancements in clinical practices and research.

Immunovia’s Mission
Founded with the mission to improve survival rates in pancreatic cancer patients through early detection, Immunovia is committed to developing and commercializing simple blood tests that detect proteins and antibodies indicative of the disease. The company collaborates with healthcare providers and patient advocacy groups to enhance accessibility and raise awareness regarding the importance of early screening, particularly in high-risk populations.

The CLARITI study signifies a major stride in achieving these objectives, potentially benefiting millions of individuals who are at increased risk for pancreatic cancer. With approximately 1.8 million individuals in the USA considered high-risk, Immunovia's innovative diagnostic approaches are expected to significantly impact public health outcomes.

Conclusion
As Immunovia prepares for the presentation at DDW 2025, the anticipation surrounding the CLARITI study results illustrates the growing momentum toward innovative solutions in the fight against pancreatic cancer. By leveraging cutting-edge science and collaboration, Immunovia aims to pave the way for more effective detection methods that can ultimately save lives.

For more information about Immunovia and its initiatives, please visit www.immunovia.com.

Contact Information:
Jeff Borcherding, CEO
Karin Almqvist Liwendahl, CFO
Email: contact@immunovia.com
Phone: +46 70 911 56 08